European Journal of Cancer
Volume 38, Issue 10 , Pages 1335-1342 , July 2002

ErbB-4 expression in limb soft-tissue sarcoma: correlation with the results of neoadjuvant chemotherapy

  • O. Merimsky

      Affiliations

    • Department of Oncology, The Tel-Aviv Sourasky Medical Center, 6 Weizman Street, 64239 Tel-Aviv, Israel1
    • Corresponding Author InformationCorresponding author. Tel.: +972-3-697-3057; fax: +972-3-697-4828
    • ,
  • J. Issakov

      Affiliations

    • Department of Pathology, The Tel-Aviv Sourasky Medical Center, 6 Weizman Street, 64239 Tel-Aviv, Israel1
    • ,
  • J. Bickels

      Affiliations

    • National Unit of Orthopedic Oncology, The Tel-Aviv Sourasky Medical Center, 6 Weizman Street, 64239 Tel-Aviv, Israel1
    • ,
  • Y. Kollender

      Affiliations

    • Department of Radiology, The Tel-Aviv Sourasky Medical Center, 6 Weizman Street, 64239 Tel-Aviv, Israel1
    • ,
  • G. Flusser

      Affiliations

    • Department of Radiology, The Tel-Aviv Sourasky Medical Center, 6 Weizman Street, 64239 Tel-Aviv, Israel1
    • ,
  • V. Soyfer

      Affiliations

    • Department of Oncology, The Tel-Aviv Sourasky Medical Center, 6 Weizman Street, 64239 Tel-Aviv, Israel1
    • ,
  • I. Schwartz

      Affiliations

    • Department of Pathology, The Tel-Aviv Sourasky Medical Center, 6 Weizman Street, 64239 Tel-Aviv, Israel1
    • ,
  • M. Inbar

      Affiliations

    • Department of Oncology, The Tel-Aviv Sourasky Medical Center, 6 Weizman Street, 64239 Tel-Aviv, Israel1
    • ,
  • I. Meller

      Affiliations

    • National Unit of Orthopedic Oncology, The Tel-Aviv Sourasky Medical Center, 6 Weizman Street, 64239 Tel-Aviv, Israel1

Received 16 August 2001 ,Revised 26 November 2001 ,Accepted 19 February 2002.

References 

  1. Le QTX, Fu KK, Kroll S, et al.  Prognostic factors in adult soft tissue sarcomas of the head and neck. Int. J. Rad. Oncol. Phys. Biol. 1997;37:975–984
  2. Rossi C, Foletto M, Alessio S, et al.  Limb sparing treatment for soft tissue sarcomas: influence of prognostic factors. J. Surg. Oncol. 1996;63:3–8
  3. Peabody TD, Monson D, Montag A, et al.  A comparison of the prognoses for deep and subcutaneous sarcomas of the extremities. J. Bone Joint Surg. 1994;76A:1167–1173
  4. Goodlad JR, Fletcher CDM, Smith MA. Surgical resection of primary soft tissue sarcoma. J. Bone Joint S.urg {Br}. 1996;78B:658–661
  5. Jensen V, Hoyer M, Sorensen FB, et al.  MIB-1 expression and iododeoxyuridine labeling in soft tissue sarcomas: an immunohistochemical study including correlations with p53, bcl-2, and histological characteristics. Histopathology. 1996;28:437–444
  6. Levine EA, Holzmayer T, Bacus S, et al.  Evaluation of newer prognostic markers for adult soft tissue sarcomas. J. Clin. Oncol. 1997;15:3249–3257
  7. Wang J, Coltreta MD, Gown AN. Abnormalities of p53 and p110RB tumor supressor gene expression in human soft tissue tumors: correlations with cell proliferation and tumor grade. Modern Pathol. 1995;8:837–842
  8. Lopes JM, Bruland OS, Bjerkehagen B, et al.  Synovial sarcoma: immunohistochemical expression of P-glycoprotein and gluthetione s transferase-pi and clinical drug resistance. Pathol. Res. Prac. 1997;193:21–36
  9. Wunder JS, Bull SB, Aneliunas V, et al.  MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J. Clin. Oncol. 2000;18:2685–2694
  10. Merimsky O, Meller I, Issakov J, et al.  Adriamycin-ifosfamide induction chemotherapy for extremity soft tissue sarcoma: comparison of two non-randomized protocols. Oncol. Rep. 1999;6:913–920
  11. Pinkas-Kramarski R, Alroy I, Yarden Y. ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. J. Mammary Gland Biol. Neoplasia. 1997;2:97–107
  12. Klapper LN, Kirschbaum MH, Sela M, et al.  Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 2000;77:25–79
  13. Slamon DJ, Godolphin W, Jones L, et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  14. Hynes N, Stern D. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta. 1994;1198:165–184
  15. Allgayer H, Babic R, Gruetzner KU, et al.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J. Clin. Oncol. 2000;18:2201–2209
  16. Fukushige S, Matsubara K, Yoshida M, et al.  Localisation of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol. Cell. Biol. 1986;6:955–958
  17. Bongiorno PF, Whyte RI, Lesser EJ, et al.  Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J. Thorac. Cardiovasc. Surg. 1994;107:590–595
  18. Mitra AB, Murty VVS, Pratap M, et al.  ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res. 1994;54:637–639
  19. Nasu K, Kawano Y, Hirota Y, et al.  Immunohistochemical study of c-erb B-2 expression in malignant mixed mullerian tumors of the female genital tract. J. Obstet. Gynaecol. Res. 1996;22:347–351
  20. Slamon DJ, Clark GM, Wong SG, et al.  Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  21. Beckhardt RN, Kiyokawa N, Liu TJ, et al.  Neu oncogene in head and neck squamous cell carcinoma. Proc. Am. Assoc. Cancer Res. 1994;35:153
  22. Mark HF, Brown S, Sun CL, et al.  Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. Pathobiology. 1998;66:59–63
  23. Andrulis IL, Bull SB, Blackstein ME, et al.  neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer: Toronto Breast Cancer Study Group. J. Clin. Oncol. 1998;16:1340–1349
  24. Sjogren S, Inganas M, Lindgren A, et al.  Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J. Clin. Oncol. 1998;16:462–469
  25. George E, Niehans GA, Swanson PE, et al.  Overexpression of the c-erbB-2 oncogene in sarcomas and small round-cell tumors of childhood. An immunohistochemical investigation. Arch. Pathol. Lab. Med. 1992;116:1033–1035
  26. Onda M, Matsuda S, Higaki S, et al.  ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer. 1996;77:71–78
  27. Gorlick R, Huvos AG, Heller G, et al.  Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma. J. Clin. Oncol. 1999;17:2781–2788
  28. Wrba F, Gullick WJ, Fertl H, et al.  Immunohistochemical detection of the c-erbB-2 proto-oncogene product in normal, benign and malignant cartilage tissues. Histopathology. 1989;15:71–76
  29. Li N, Shen LH, Zhu QF. Overexpression of c-erbB-2 proto-oncogene product in chondrosarcomas. Chung Hua Ping Li Hsueh Tsa Chih. 1994;23:37–39
  30. Sawyer C, Hiles I, Page M, et al.  Two erbB-4 transcripts are expressed in normal breast and in most breast cancers. Oncogene. 1998;17:919–924
  31. Srinivasan R, Poulsom R, Hurst HC, et al.  Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J. Pathol. 1998;185:236–245
  32. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Manual for Staging of Cancer. 4th ed.. Philadelphia: JB Lippincott; 1992;
  33. Huvos, A., 1991. Bone Tumors: Diagnosis, Treatment and Prognosis. WB Saunders, Philadelphia, USA.
  34. Merimsky O, Staroselsky A, Inbar M, Schwartz Y, Wigler N, Mann A, et al. Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small cell lung cancer. Ann. Oncol. 2001;12:1127–1131
  35. Haugen DR, Akslen LA, Varhaug JE, et al.  Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res. 1996;56:1184–1188
  36. Srinivasan R, Benton E, McCormick F, et al.  Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. Clin. Cancer Res. 1999;5:2877–2883
  37. Srinivasan R, Gillett CE, Barnes DM, et al.  Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res. 2000;60:1483–1487
  38. Kew TY, Bell JA, Pinder SE, et al.  c-erbB-4 protein expression in human breast cancer. Br. J. Cancer. 2000;82:1163–1170
  39. Pisters PWT, Patel SR, Varma DGK, et al.  Preoperative chemotherapy for stage IIIB extremity soft tissue sarcomas: Long term results from a single institution. J. Clin. Oncol. 1997;15:3481–3487
  40. Eilber FC, Rosen G, Eckardt J, et al.  Treatment induced pathological necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade soft tissue sarcomas. J. Clin. Oncol. 2001;19:3203–3209

PII: S0959-8049(02)00075-8

European Journal of Cancer
Volume 38, Issue 10 , Pages 1335-1342 , July 2002

Article Tools

* Image Usage & Resolution